Text Messaging Intervention to Improve HIV Adherence in Rural Drug Users (TEXTR34)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Many drug users living with HIV demonstrate inadequate levels of medication adherence, and are at high risk for disengaging from care. HIV positive drug users are at even higher risk of poor medication adherence and treatment dropout when living far from treatment centers. Rural residence is common in the U.S. South where rates of new HIV infections are disproportionately high, especially among ethnic minorities. While there are efficacious interventions to improve HIV treatment adherence, only a few have targeted drug users, and these have required patients to come into research clinics for adherence interventions. Transportation problems, poverty, isolation, and stigma are known barriers to accessing adherence support among rural drug users with HIV.Additionally, most adherence interventions aim to increase adherence, but come too late, unable to respond in real time to adherence lapses to help patients re-initiate appropriate medication use while remaining in their natural environments. There is a pressing need to develop tailored, scalable interventions that detect nonadherence episodes in real time and enhance adherence to HIV treatment immediately. Building interventions upon familiar, existing technology could extend their reach into communities of non-urban patients living with HIV, overcoming common barriers to care, and could ultimately be scaled up to help drug using HIV+ patients nationwide.
The investigators propose to develop and test the feasibility and promise of a combined HIV adherence assessment and intervention application for rural drug users using an available, familiar technology whose reach will grow exponentially: text messaging via mobile phones. By 2007, 84% of U.S. residents had mobile phones, with near 100% mobile phone penetration projected by 2013. While technology adoption is often slower in under-served communities, the trend is different with mobile phone technology. African-Americans are using more mobile phone minutes per capita and increasing their use at a higher rate compared with other ethnic groups. This technology has great potential to reduce health disparities. In this project, the investigators will develop and test the feasibility and promise of a text messaging application and system using Ecological Momentary Assessment methods to detect nonadherence and drug use and immediately intervene to improve HIV treatment adherence in drug users living with HIV/AIDS who reside outside major metropolitan areas. This R34 is a Stage 1b/2a project in the Stage Model of Behavioral Therapy Development that will develop novel interventions and methods, and generate preliminary estimates of effect sizes that will determine whether a larger clinical trial with extended follow-up and cost-effectiveness evaluation is warranted.
The specific aims of this project are:
To identify assessment and intervention features relevant to the adherence barriers and drug use patterns of rural and non-urban HIV+ drug users using formative methods including:
- structured interviews and focus groups to identify specific barriers to adherence and engagement in care and needs related to drug craving and drug use that should be addressed by the intervention
- iterative usability testing of components and drafts of the intervention
To create a text messaging mobile phone application and system (Treatment Extension by Texting, Text) to assess and improve HIV treatment adherence and drug use in real time
--Text will be built upon a piloted unidirectional personalized text phone application and system, STeM, and will include pre- and post-programming usability testing
To test the feasibility and promise of the assessment and intervention tool in a randomized pilot trial of rural HIV+ drug users with detectable viral load (VL) comparing Text to usual care
- Feasibility: Identify recruitment rates, consent rates, participant flow, completion rates, and variance of key covariates and outcome variables
- Promise: determine point estimates and the precision of effects for primary and secondary adherence outcomes including pharmacy refills and unannounced pill counts (medication adherence), missed visit percentage (treatment engagement), VL, and drug craving and drug use.
| Condition | Intervention |
|---|---|
|
HIV Infections |
Behavioral: Text messaging plus EMA Behavioral: Treatment as usual |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | RCT of a Text Messaging Adherence Assessment & Intervention Tool for Rural HIV+ Drug Users |
- Missed Visit Proportion (MVP) [ Time Frame: 6 months ] [ Designated as safety issue: No ]The primary outcome measure for ADHERENCE is missed visit proportion (MVP) across a 6 month follow-up period, used to derive the sample size for this stage 1 RCT. The primary outcome measure for DRUG USE is a Timeline Follow-back to gather 90 day retrospective reports of daily drug use.
- pharmacy refill data [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]Secondary outcome measures for adherence will be unannounced telephone pill counts and pharmacy refill data; these will be assessed and used to plan a larger, more definitive study, if the intervention shows promise. Pharmacy compliance can be measured directly in the large subset of patients who fill their prescription through the Virginia ADAP Program. Unannounced pill counts conducted by phone can be assessed for all participants and used to measure medication adherence.
- Secondary: text messaged adherence and drug use data [ Time Frame: during 12 week intervention period ] [ Designated as safety issue: No ]We will have daily data from participants' text messages about their adherence behavior. Comparing texts sent by participants about adherence to TLFB will allow us to test the level of agreement about adherence by two distinct measures, one (TLFB) with known properties. Differences in the magnitude and direction of the effect of the intervention for different outcomes will help us choose an outcome for the larger trial, and may shed light on the particular aspects of behavior that the text messaging tool can influence.
| Estimated Enrollment: | 70 |
| Study Start Date: | May 2011 |
| Estimated Study Completion Date: | June 2013 |
| Estimated Primary Completion Date: | May 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Text messaging
Participants randomized to this arm will receive a mobile phone if needed, and the 12 week personalized text messaging/EMA intervention
|
Behavioral: Text messaging plus EMA
Personalized, tailored text messaging to prompt medication adherence, with EMA random queries about nonadherence and drug use, and two-way messaging for participants to report critical events
|
|
Active Comparator: Treatment as usual
Participants randomized to this arm will receive treatment as usual in the ID clinics and in the communities for nonadherence and drug use problems
|
Behavioral: Treatment as usual
usual care in one of the three participating ID clinics, along with usual care (if any) in the community for problematic drug and alcohol use
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18 or older
- has a detectable viral load
- reports use of at least one illicit drug in last 30 days
- requires ART
- able to receive mobile phone service at home address
Exclusion Criteria:
- lack of English proficiency
- planning to move out of area in the next six months
- inability to provide consent.
Note regarding "inability to provide consent": Traditionally, some patients with HIV whom we evaluate for potential participation in research studies are not able to provide informed consent, either due to significant cognitive decline, or their designation of someone else as their legal proxy. When this occurs, we do not offer them study participation because legally, they are unable to consent, even if currently, their cognitive capacities seem intact. We have generally assessed this through a series of branching questions to determine their legal and cognitive capacity for consent.
Contacts and Locations| Contact: Karen S Ingersoll, Ph.D. | 434-243-0581 | kareningersoll@virginia.edu |
| Contact: Rebecca Dillingham, M.D. | (434) 982-0103 | RD8V@virginia.edu |
| United States, Virginia | |
| UVA Infectious Diseases Clinic | Not yet recruiting |
| Charlottesville, Virginia, United States, 22903 | |
| Principal Investigator: Karen S Ingersoll, Ph.D. | |
| Principal Investigator: | Karen S Ingersoll, Ph.D. | University of Virginia |
More Information
No publications provided
| Responsible Party: | Karen S. Ingersoll Ph.D., Department of Psychiatry and Neurobehavioral Sciences |
| ClinicalTrials.gov Identifier: | NCT01343654 History of Changes |
| Other Study ID Numbers: | 15475 |
| Study First Received: | April 26, 2011 |
| Last Updated: | May 13, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Virginia:
|
HIV medication adherence drug use rural nonadherence to HIV medications |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on May 16, 2013